Detection	O
of	O
lymphovascular	B-Multi-tissue_structure
invasion	O
in	O
early	O
breast	B-Cancer
cancer	I-Cancer
by	O
D2	O
-	O
40	O
(	O
podoplanin	O
)	O
:	O
a	O
clinically	O
useful	O
predictor	O
for	O
axillary	B-Cancer
lymph	I-Cancer
node	I-Cancer
metastases	I-Cancer
.	O

PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
use	O
of	O
D2	O
-	O
40	O
for	O
the	O
detection	O
of	O
lymphovascular	B-Multi-tissue_structure
invasion	O
(	O
LVI	O
)	O
in	O
node	B-Multi-tissue_structure
positive	O
and	O
negative	O
early	O
breast	B-Cancer
cancer	I-Cancer
.	O

LVI	O
is	O
associated	O
with	O
axillary	B-Cancer
lymph	I-Cancer
node	I-Cancer
metastases	I-Cancer
(	O
ALNM	B-Cancer
)	O
and	O
a	O
long	O
-	O
term	O
prognostic	O
factor	O
.	O

A	O
precise	O
identification	O
of	O
LVI	O
would	O
have	O
a	O
strong	O
clinical	O
impact	O
for	O
breast	B-Cancer
cancer	I-Cancer
patients	O
.	O

METHODS	O
:	O
Immunohistochemical	O
staining	O
with	O
D2	O
-	O
40	O
and	O
CD34	O
was	O
performed	O
on	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	B-Tissue
sections	I-Tissue
of	O
254	O
invasive	B-Cancer
breast	I-Cancer
tumors	I-Cancer
of	O
247	O
patients	O
with	O
node	B-Multi-tissue_structure
negative	O
and	O
node	B-Multi-tissue_structure
positive	O
early	O
breast	B-Cancer
cancer	I-Cancer
.	O

All	O
slides	O
were	O
screened	O
for	O
the	O
presence	O
of	O
LVI	O
.	O

Correlation	O
with	O
clinico	O
-	O
pathological	O
factors	O
including	O
LVI	O
as	O
retrieved	O
by	O
routine	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
.	O
E	O
.	O
)	O
stained	O
sections	B-Tissue
and	O
the	O
eligibility	O
for	O
the	O
prediction	O
of	O
ALNM	O
was	O
assessed	O
.	O

RESULTS	O
:	O
Using	O
the	O
D2	O
-	O
40	O
antibody	O
for	O
immunostaining	O
,	O
our	O
results	O
demonstrate	O
a	O
significant	O
higher	O
detection	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
of	O
LVI	O
as	O
compared	O
with	O
routine	O
H	O
.	O
E	O
.	O
-	O
staining	O
in	O
early	O
breast	B-Cancer
cancer	I-Cancer
.	O

LVI	O
was	O
correctly	O
identified	O
by	O
D2	O
-	O
40	O
(	O
D2	O
-	O
40	O
+	O
)	O
in	O
70	O
out	O
of	O
254	O
tumors	B-Cancer
(	O
28	O
%	O
)	O
as	O
compared	O
to	O
40	O
tumors	B-Cancer
(	O
16	O
%	O
)	O
by	O
routine	O
HE	O
staining	O
(	O
HE	O
+	O
)	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
D2	O
-	O
40	O
+	O
LVI	O
and	O
age	O
,	O
t	O
-	O
stage	O
,	O
nodal	B-Multi-tissue_structure
status	O
,	O
grading	O
and	O
hormonreceptor	O
-	O
status	O
.	O

Correlation	O
between	O
D2	O
-	O
40	O
+	O
LVI	O
and	O
menopausal	O
-	O
status	O
,	O
HER2	O
-	O
status	O
and	O
histological	O
type	O
was	O
not	O
significant	O
,	O
while	O
there	O
was	O
a	O
significant	O
correlation	O
of	O
D2	O
-	O
40	O
and	O
so	O
called	O
"	O
triple	O
negative	O
"	O
tumors	B-Cancer
(	O
ER	O
/	O
PR	O
and	O
HER2neu	O
-	O
negative	O
)	O
.	O

In	O
a	O
multivariate	O
analysis	O
D2	O
-	O
40	O
+	O
was	O
the	O
strongest	O
predictor	O
for	O
ALNM	O
with	O
an	O
odds	O
ratio	O
of	O
3	O
.	O
489	O
and	O
a	O
P	O
-	O
value	O
of	O
P	O
=	O
0	O
.	O
0003	O
,	O
followed	O
only	O
by	O
T	O
-	O
stage	O
and	O
grading	O
with	O
odds	O
ratios	O
of	O
3	O
.	O
167	O
and	O
1	O
.	O
953	O
and	O
P	O
-	O
values	O
P	O
=	O
0	O
.	O
0003	O
and	O
P	O
=	O
0	O
.	O
0352	O
.	O

CONCLUSION	O
:	O
Immunostaining	O
with	O
D2	O
-	O
40	O
significantly	O
increased	O
the	O
frequency	O
of	O
detection	O
of	O
lymphatic	B-Multi-tissue_structure
invasion	O
compared	O
to	O
conventional	O
H	O
.	O
E	O
.	O
-	O
staining	O
in	O
early	O
breast	B-Cancer
cancer	I-Cancer
.	O

As	O
LVI	O
is	O
a	O
strong	O
predictive	O
and	O
prognostic	O
marker	O
,	O
the	O
monoclonal	O
antibody	O
D2	O
-	O
40	O
has	O
the	O
potential	O
to	O
play	O
a	O
significant	O
role	O
in	O
pathological	O
routine	O
workup	O
of	O
breast	B-Cancer
tumors	I-Cancer
.	O

Further	O
prospective	O
studies	O
are	O
needed	O
to	O
prove	O
the	O
clinical	O
impact	O
of	O
D2	O
-	O
40	O
.	O

